|
EP0569525A1
(en)
|
1991-02-01 |
1993-11-18 |
Coulter Corporation |
METHOD OF PRODUCING F(ab') 2? FRAGMENTS OF IMMUNOGLOBULINS
|
|
US6090382A
(en)
|
1996-02-09 |
2000-07-18 |
Basf Aktiengesellschaft |
Human antibodies that bind human TNFα
|
|
BRPI9707379C8
(pt)
|
1996-02-09 |
2017-12-12 |
Abbott Biotech Ltd |
composições farmacêuticas compreendendo anticorpo humano recombinante geneticamente engenheirado, e anticorpo humano recombinante geneticamente engenheirado.
|
|
KR100960211B1
(ko)
|
1998-05-06 |
2010-05-27 |
제넨테크, 인크. |
이온 교환 크로마토그래피에 의한 단백질 정제 방법
|
|
CA2385745C
(en)
|
2001-06-08 |
2015-02-17 |
Abbott Laboratories (Bermuda) Ltd. |
Methods of administering anti-tnf.alpha. antibodies
|
|
MY151032A
(en)
|
2002-07-19 |
2014-03-31 |
Abbott Lab S A |
Treatment of tnf? related disorders
|
|
US20040033228A1
(en)
|
2002-08-16 |
2004-02-19 |
Hans-Juergen Krause |
Formulation of human antibodies for treating TNF-alpha associated disorders
|
|
MY150740A
(en)
|
2002-10-24 |
2014-02-28 |
Abbvie Biotechnology Ltd |
Low dose methods for treating disorders in which tnf? activity is detrimental
|
|
US8227241B2
(en)
|
2004-03-12 |
2012-07-24 |
Unigene Laboratories, Inc. |
Bacterial host cell for the direct expression of peptides
|
|
TW201705980A
(zh)
|
2004-04-09 |
2017-02-16 |
艾伯維生物技術有限責任公司 |
用於治療TNFα相關失調症之多重可變劑量療法
|
|
WO2006096490A2
(en)
|
2005-03-08 |
2006-09-14 |
Pharmacia & Upjohn Company Llc |
ANTI-MAdCAM ANTIBODY COMPOSITIONS
|
|
KR20150055116A
(ko)
|
2005-05-16 |
2015-05-20 |
애브비 바이오테크놀로지 리미티드 |
미란성 다발관절염의 치료를 위한 tnf 억제제의 용도
|
|
US20110008831A1
(en)
|
2005-05-26 |
2011-01-13 |
Cytos Biotechnology Ag |
Scalable fermentation process
|
|
RS52861B
(sr)
|
2005-06-07 |
2013-12-31 |
Esbatech - A Novartis Company Llc |
Stabilna i rastvorljiva antitela koja inhibiraju tnf (alfa)
|
|
US20070041905A1
(en)
|
2005-08-19 |
2007-02-22 |
Hoffman Rebecca S |
Method of treating depression using a TNF-alpha antibody
|
|
US7612181B2
(en)
|
2005-08-19 |
2009-11-03 |
Abbott Laboratories |
Dual variable domain immunoglobulin and uses thereof
|
|
PE20070796A1
(es)
|
2005-10-24 |
2007-08-15 |
Wyeth Corp |
Metodo de produccion proteica utilizando compuestos anti-senescencia
|
|
NZ567286A
(en)
|
2005-11-01 |
2012-03-30 |
Abbott Biotechnolgy Ltd |
Methods and compositions for diagnosing ankylosing spondylitis using biomarkers
|
|
NZ611859A
(en)
|
2006-04-05 |
2014-12-24 |
Abbvie Biotechnology Ltd |
Antibody purification
|
|
US9605064B2
(en)
|
2006-04-10 |
2017-03-28 |
Abbvie Biotechnology Ltd |
Methods and compositions for treatment of skin disorders
|
|
WO2007120626A2
(en)
|
2006-04-10 |
2007-10-25 |
Abbott Biotechnology Ltd. |
Uses and compositions for treatment of ankylosing spondylitis
|
|
WO2007120656A2
(en)
|
2006-04-10 |
2007-10-25 |
Abbott Biotechnology Ltd. |
Uses and compositions for treatment of rheumatoid arthritis
|
|
EP2666472A3
(en)
|
2006-04-10 |
2014-04-02 |
Abbott Biotechnology Ltd |
Uses and compositions for treatment of psoriatic arthritis
|
|
EP2666478A3
(en)
|
2006-04-10 |
2014-10-22 |
AbbVie Biotechnology Ltd |
Uses and compositions for treatment of psoriasis
|
|
CA2564435A1
(en)
|
2006-04-10 |
2007-10-10 |
Abbott Biotechnology Ltd. |
Methods for monitoring and treating intestinal disorders
|
|
US20080118496A1
(en)
|
2006-04-10 |
2008-05-22 |
Medich John R |
Uses and compositions for treatment of juvenile rheumatoid arthritis
|
|
US7846724B2
(en)
|
2006-04-11 |
2010-12-07 |
Hoffmann-La Roche Inc. |
Method for selecting CHO cell for production of glycosylated antibodies
|
|
US20080311043A1
(en)
|
2006-06-08 |
2008-12-18 |
Hoffman Rebecca S |
Uses and compositions for treatment of psoriatic arthritis
|
|
US20100021451A1
(en)
|
2006-06-08 |
2010-01-28 |
Wong Robert L |
Uses and compositions for treatment of ankylosing spondylitis
|
|
JP5535623B2
(ja)
|
2006-06-30 |
2014-07-02 |
アッヴィ バイオテクノロジー リミテッド |
自動注射装置
|
|
JP5437633B2
(ja)
|
2006-09-11 |
2014-03-12 |
株式会社 免疫生物研究所 |
モノクローナル抗体およびその用途
|
|
US8911964B2
(en)
|
2006-09-13 |
2014-12-16 |
Abbvie Inc. |
Fed-batch method of making human anti-TNF-alpha antibody
|
|
CN103276033A
(zh)
|
2006-09-13 |
2013-09-04 |
雅培制药有限公司 |
细胞培养改良
|
|
EP2500416A1
(en)
|
2006-09-13 |
2012-09-19 |
Abbott Laboratories |
Cell culture improvements
|
|
EP2684895A1
(en)
|
2006-10-27 |
2014-01-15 |
AbbVie Biotechnology Ltd |
Crystalline anti-hTNFalpha antibodies
|
|
CA2681581A1
(en)
|
2007-03-30 |
2008-10-09 |
Abbott Laboratories |
Recombinant expression vector elements (reves) for enhancing expression of recombinant proteins in host cells
|
|
TWI601823B
(zh)
|
2007-04-26 |
2017-10-11 |
Chugai Pharmaceutical Co Ltd |
Cell culture methods using media containing high concentrations of amino acids
|
|
EP2165194A4
(en)
|
2007-05-31 |
2010-09-08 |
Abbott Lab |
BIOMARKERS FOR PREDICTING RESPONSABILITY TO TNF ALPHA INHIBITORS IN AUTOIMMUNE DISEASES
|
|
WO2008154543A2
(en)
|
2007-06-11 |
2008-12-18 |
Abbott Biotechnology Ltd. |
Methods for treating juvenile idiopathic arthritis
|
|
UA107557C2
(xx)
*
|
2007-07-06 |
2015-01-26 |
|
Композиція антитіла офатумумабу
|
|
WO2009020654A1
(en)
|
2007-08-08 |
2009-02-12 |
Abbott Laboratories |
Compositions and methods for crystallizing antibodies
|
|
ES2750254T3
(es)
|
2007-09-27 |
2020-03-25 |
Amgen Inc |
Formulaciones farmacéuticas
|
|
US8883146B2
(en)
|
2007-11-30 |
2014-11-11 |
Abbvie Inc. |
Protein formulations and methods of making same
|
|
TWI543768B
(zh)
|
2007-11-30 |
2016-08-01 |
艾伯維生物技術有限責任公司 |
蛋白質調配物及製造其之方法
|
|
WO2009073805A2
(en)
*
|
2007-12-04 |
2009-06-11 |
Verdezyne, Inc. |
Aglycosylated therapeutic antibodies and therapeutic antibody-encoding nucleotide sequences
|
|
SG2013054218A
(en)
|
2008-01-15 |
2014-10-30 |
Abbott Gmbh & Co Kg |
Powdered protein compositions and methods of making same
|
|
ATE460666T1
(de)
|
2008-01-15 |
2010-03-15 |
Univ Utrecht Holding Bv |
Verfahren zur bestimmung der aminosäurensequenz von peptiden
|
|
WO2009091912A2
(en)
|
2008-01-15 |
2009-07-23 |
Abbott Laboratories |
Improved mammalian expression vectors and uses thereof
|
|
TWI472339B
(zh)
|
2008-01-30 |
2015-02-11 |
Genentech Inc |
包含結合至her2結構域ii之抗體及其酸性變異體的組合物
|
|
EP2271671A2
(en)
|
2008-03-24 |
2011-01-12 |
Abbott Biotechnology Ltd. |
Tnf-alpha inhibitors for treating bone loss
|
|
CA2723197C
(en)
|
2008-05-02 |
2017-09-19 |
Seattle Genetics, Inc. |
Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation
|
|
CN104974251A
(zh)
|
2008-10-20 |
2015-10-14 |
Abbvie公司 |
在抗体纯化过程中的病毒灭活
|
|
CN102257004A
(zh)
|
2008-10-20 |
2011-11-23 |
雅培制药有限公司 |
与il-12结合的抗体及其纯化方法
|
|
CN105111309A
(zh)
|
2008-10-20 |
2015-12-02 |
Abbvie公司 |
使用a蛋白亲和层析分离和纯化抗体
|
|
KR101593285B1
(ko)
|
2008-10-29 |
2016-02-11 |
아블린쓰 엔.브이. |
단일 도메인 항원 결합 분자의 제형
|
|
EP2350649A4
(en)
|
2008-11-28 |
2012-11-14 |
Abbott Lab |
STABLE ANTIBODY COMPOSITIONS AND METHODS FOR STABILIZING THE SAME
|
|
KR20120034593A
(ko)
|
2009-03-09 |
2012-04-12 |
유니버시티 오브 조지아 리서치 파운데이션 인코퍼레이티드 |
위암 진단용 단백질 마커의 동정
|
|
WO2010129469A1
(en)
|
2009-05-04 |
2010-11-11 |
Abbott Biotechnology Ltd. |
Stable high protein concentration formulations of human anti-tnf-alpha-antibodies
|
|
ES2527173T3
(es)
|
2009-06-02 |
2015-01-21 |
Regeneron Pharmaceuticals, Inc. |
Células de fucosilación deficiente
|
|
WO2010141855A1
(en)
|
2009-06-05 |
2010-12-09 |
Momenta Pharmaceuticals, Inc. |
Methods of modulating fucosylation of glycoproteins
|
|
US20110059079A1
(en)
|
2009-09-04 |
2011-03-10 |
Xoma Technology Ltd. |
Antibody Coformulations
|
|
AR078161A1
(es)
|
2009-09-11 |
2011-10-19 |
Hoffmann La Roche |
Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
|
|
EP2538973A2
(en)
|
2010-02-26 |
2013-01-02 |
Novo Nordisk A/S |
Stable antibody containing compositions
|
|
US9072668B2
(en)
|
2010-03-09 |
2015-07-07 |
Janssen Biotech, Inc. |
Non-aqueous high concentration reduced viscosity suspension formulations of antibodies
|
|
BR112012030530A2
(pt)
|
2010-05-18 |
2022-12-20 |
Abbvie Inc |
Aparelho e processo para purificação de proteínas
|
|
EP4492053A3
(en)
|
2010-05-25 |
2025-03-19 |
F. Hoffmann-La Roche AG |
Methods of purifying polypeptides
|
|
RS57543B1
(sr)
|
2010-06-03 |
2018-10-31 |
Abbvie Biotechnology Ltd |
Primene i kompozicije za lečenje hidradenitis suppurativa (hs)
|
|
MX2013003182A
(es)
|
2010-09-20 |
2013-04-24 |
Abbvie Inc |
Purificacion de anticuerpos por cromatografia de lecho movil simulada.
|
|
US20120258496A1
(en)
|
2010-09-27 |
2012-10-11 |
Boehringer Ingelheim International Gmbh |
Production of low fucose antibodies in h4-ii-e rat cells
|
|
MX344268B
(es)
|
2010-10-11 |
2016-12-09 |
Abbvie Inc * |
Proceso para purificacion de proteinas.
|
|
JP5919606B2
(ja)
|
2010-11-11 |
2016-05-18 |
アッヴィ バイオテクノロジー リミテッド |
改良型高濃度抗tnfアルファ抗体液体製剤
|
|
SG191371A1
(en)
|
2010-12-28 |
2013-08-30 |
Chugai Pharmaceutical Co Ltd |
Animal cell culturing method
|
|
EP2702077A2
(en)
|
2011-04-27 |
2014-03-05 |
AbbVie Inc. |
Methods for controlling the galactosylation profile of recombinantly-expressed proteins
|
|
CA2831572C
(en)
|
2011-05-02 |
2019-11-26 |
Immunomedics, Inc. |
Ultrafiltration concentration of allotype selected antibodies for small-volume administration
|
|
IL288509B2
(en)
|
2011-07-01 |
2023-04-01 |
Amgen Inc |
Mammalian cell culture
|
|
GB201112429D0
(en)
|
2011-07-19 |
2011-08-31 |
Glaxo Group Ltd |
Antigen-binding proteins with increased FcRn binding
|
|
CA2850668A1
(en)
|
2011-10-04 |
2013-04-11 |
Expression Pathology, Inc. |
Srm/mrm assay for the ephrin type-a receptor 2 protein
|
|
IN2014CN03936A
(OSRAM)
|
2011-10-24 |
2015-09-04 |
Abbvie Inc |
|
|
EP2773439A4
(en)
|
2011-10-31 |
2015-07-01 |
Merck Sharp & Dohme |
CHROMATOGRAPHY METHOD FOR RESOLVING HETEROGENIC ANTIBODY AGGREGATES
|
|
WO2013114165A1
(en)
|
2012-01-30 |
2013-08-08 |
Dr Reddy's Laboratories Limited |
Process of obtaining glycoprotein composition with increased afucosylation content
|
|
WO2013114164A1
(en)
|
2012-01-30 |
2013-08-08 |
Dr. Reddy's Laboratories Limited |
Method for obtaining glycoprotein composition with increased afucosylation content
|
|
WO2013158273A1
(en)
|
2012-04-20 |
2013-10-24 |
Abbvie Inc. |
Methods to modulate c-terminal lysine variant distribution
|
|
US9150645B2
(en)
|
2012-04-20 |
2015-10-06 |
Abbvie, Inc. |
Cell culture methods to reduce acidic species
|
|
US9067990B2
(en)
|
2013-03-14 |
2015-06-30 |
Abbvie, Inc. |
Protein purification using displacement chromatography
|
|
US9249182B2
(en)
|
2012-05-24 |
2016-02-02 |
Abbvie, Inc. |
Purification of antibodies using hydrophobic interaction chromatography
|
|
EP2863951A1
(en)
|
2012-06-12 |
2015-04-29 |
Boehringer Ingelheim International GmbH |
Pharmaceutical formulation for a therapeutic antibody
|
|
US9512214B2
(en)
|
2012-09-02 |
2016-12-06 |
Abbvie, Inc. |
Methods to control protein heterogeneity
|
|
SG11201501715QA
(en)
|
2012-09-07 |
2015-05-28 |
Coherus Biosciences Inc |
Stable aqueous formulations of adalimumab
|
|
JP5874587B2
(ja)
|
2012-09-10 |
2016-03-02 |
株式会社島津製作所 |
アミノ酸配列解析方法及び装置
|
|
NO2760138T3
(OSRAM)
|
2012-10-01 |
2018-08-04 |
|
|
|
JP2015531244A
(ja)
|
2012-10-15 |
2015-11-02 |
ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company |
タンパク質を製造するための哺乳動物細胞培養方法
|
|
US9844594B2
(en)
|
2012-12-18 |
2017-12-19 |
Merck Sharp & Dohme Corp. |
Liquid formulations for an anti-TNF α antibody
|
|
EP2938323A2
(en)
|
2012-12-28 |
2015-11-04 |
Abbott Cardiovascular Systems, Inc. |
Therapeutic compositions comprising antibodies
|
|
EP2830651A4
(en)
|
2013-03-12 |
2015-09-02 |
Abbvie Inc |
HUMAN ANTIBODIES THAT BIND TNF-ALPHA AND PREPARATION METHODS
|
|
WO2014151901A1
(en)
|
2013-03-14 |
2014-09-25 |
Abbvie Inc. |
Improvement of mammalian cell culture performance through surfactant supplementation of feed media
|
|
CA2926384A1
(en)
|
2013-03-14 |
2014-10-02 |
Abbvie Inc. |
Low acidic species compositions and methods for producing and using the same
|
|
US9217168B2
(en)
|
2013-03-14 |
2015-12-22 |
Momenta Pharmaceuticals, Inc. |
Methods of cell culture
|
|
WO2014175164A1
(ja)
|
2013-04-25 |
2014-10-30 |
株式会社カネカ |
Fab型抗体の分泌量を増大できるFd鎖遺伝子又はL鎖遺伝子
|
|
US9416181B2
(en)
|
2013-05-06 |
2016-08-16 |
Abbvie Inc. |
Compositions for cell culture and methods of using the same
|
|
TWI596107B
(zh)
|
2013-06-25 |
2017-08-21 |
卡地拉保健有限公司 |
單株抗體之新穎純化方法
|
|
WO2015051310A2
(en)
|
2013-10-03 |
2015-04-09 |
Bioanalytix, Inc. |
Mass spectrometry-based method for identifying and maintaining quality control factors during the development and manufacture of a biologic
|
|
WO2015057910A1
(en)
|
2013-10-16 |
2015-04-23 |
Oncobiologics, Inc. |
Buffer formulations for enhanced antibody stability
|
|
US9085618B2
(en)
|
2013-10-18 |
2015-07-21 |
Abbvie, Inc. |
Low acidic species compositions and methods for producing and using the same
|
|
WO2015140700A1
(en)
|
2014-03-19 |
2015-09-24 |
Dr. Reddy's Laboratories Limited |
Cell culture process
|
|
LT2946765T
(lt)
|
2014-05-23 |
2016-11-25 |
Ares Trading S.A. |
Skysta farmacinė kompozicija
|
|
HUP1400510A1
(hu)
*
|
2014-10-28 |
2016-05-30 |
Richter Gedeon Nyrt |
Gyógyászati TNFalfa ellenes antitest készítmény
|
|
CN105044222B
(zh)
|
2014-12-19 |
2017-09-12 |
浙江辉肽生命健康科技有限公司 |
生物活性多肽的分析测试和鉴定方法
|
|
EP3247718B1
(en)
|
2015-01-21 |
2021-09-01 |
Outlook Therapeutics, Inc. |
Modulation of charge variants in a monoclonal antibody composition
|
|
UY36542A
(es)
|
2015-01-28 |
2016-08-31 |
Mabxience S A |
Formulaciones farmacéuticas para anticuerpos anti-tnf-alfa
|
|
CN105779394B
(zh)
|
2015-03-20 |
2020-03-24 |
广东东阳光药业有限公司 |
一种降低抗体酸性峰含量和改良抗体糖型的细胞培养方法
|
|
CA3010598A1
(en)
|
2016-01-06 |
2017-07-13 |
Oncobiologics, Inc. |
Modulation of afucosylated species in a monoclonal antibody composition
|
|
US20190048070A1
(en)
|
2016-01-06 |
2019-02-14 |
Oncobiologics, Inc. |
Reduction of high molecular weight species, acidic charge species and fragments in a monoclonal antibody composition
|
|
WO2017136433A1
(en)
|
2016-02-03 |
2017-08-10 |
Oncobiologics, Inc. |
Buffer formulations for enhanced antibody stability
|
|
JP7224914B2
(ja)
|
2016-02-04 |
2023-02-20 |
アウトルック セラピューティクス,インコーポレイティド |
タンパク質のアミノ酸配列の同定及び分析方法
|